Remdesivir Intermediate CAS 1911578-98-7 2-Ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate

Short Description:

Chemical Name: 2-Ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate

CAS: 1911578-98-7

Appearance: White to Off-White Powder Purity: ≥98.0%

Intermediate of Remdesivir (CAS 1809249-37-3) COVID-19

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name 2-Ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate
Synonyms N-[(S)-(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphinyl]-L-Alanine 2-ethylbutyl ester; Remdesivir Intermediate; Remdesivir-001; Remdesivir Impurity 21
CAS Number 1911578-98-7
CAT Number RF-PI303
Stock Status In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula C21H27N2O7P
Molecular Weight 495.38
Density 1.2g/cm3
Melting Point 92.0~96.0℃(lit.)
Boiling Point 356.7℃ at 760 mmHg
Shipping Condition Shipped Under Ambient Temperature
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White to Off-White Powder
Infrared Spectrum Conforms to Structure
Purity ≥99.0% 
Loss on Drying ≤0.50%
Single Impurity ≤0.50%
Total Impurities ≤1.0%
Heavy Metals ≤20ppm
Test Standard Enterprise Standard
Usage Intermediate of Remdesivir (CAS 1809249-37-3) 

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

1

FAQ:

Application:

2-Ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alaninate (CAS 1911578-98-7) is an advanced key intermediate in the preparation of Remdesivir related analogs. Remdesivir is a monophosphoramidate prodrug of an adenosine analog, is an investigational broad-spectrum antiviral agent with in vitro activity against SARS coronavirus, MERS coronavirus and, more recently, Covid-19. Remdesivir was mainly developed as a treatment for filovirus infections such as Ebola virus disease or Marburg virus. Subsequently, Remdesivir was found to show antiviral activity against other single-stranded RNA viruses such as respiratory syncytial virus, Nipah virus, Hendra virus, Junin virus, Lassa fever virus and the coronaviruses (including MERS and SARS viruses). Recently it is being studied as a promising medication for the treatment of COVID-19 (new SARS type virus). Remdesivir, developed by Gilead Sciences, is an adenosine prodrug that metabolizes into its active form GS-441524 which interferes with the action of viral RNA-dependent RNA polymerase and evades proofreading by viral exoribonuclease (ExoN), causing a decrease in viral RNA production.

  • Write your message here and send it to us